ArticleJournal of translational medicine2026
Exosomes derived from human umbilical cord mesenchymal stem cells attenuate neuroinflammation in intracerebral hemorrhage rats by modulating lactylation modification.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundNeuroinflammation following intracerebral hemorrhage (ICH) is a critical contributor to secondary brain injury. Lactylation modification, a novel epigenetic regulatory mechanism, may participate in pathological processes by modulating inflammatory gene expression. This study investigates whether exosomes derived from human umbilical cord mesenchymal stem cells (hUCMSC-exos) alleviate ICH-induced neuroinflammation by regulating lactylation modification via the PI3K/AKT/PKM2/H3K18la axis.
methodsIn vivo, an ICH model was established by stereotactic injection of collagenase IV into the rat striatum. At 6 h post-ICH, hUCMSC-exos (100 μg/200 μL) were administered via tail vein. In vitro, a hemin-induced (20 μM) ICH cell model was established using primary astrocytes, followed by hUCMSC-exos treatment (20 μg/mL) at 6 h post-modeling. The expression of the PI3K/AKT/PKM2/H3K18la axis and inflammatory cytokines (TNF-α, IL-1β, and IL-10) was evaluated in both models to assess the impact of hUCMSC-exos on glycolysis, lactylation modification, and neuroinflammation. Neurological function in ICH rats was evaluated using corner turn, forelimb placement, Longa, and Bederson scores at days 1, 3, 7, and 14.
resultshUCMSC-exos intervention significantly upregulated phosphorylated PI3K (p-PI3K) and AKT (p-AKT) levels, while downregulating PKM2, LDHA, and H3K18la expression. Pro-inflammatory cytokines (TNF-α and IL-1β) were markedly reduced, whereas the anti-inflammatory cytokine IL-10 was elevated. Consequently, hUCMSC-exos improved neurological recovery in ICH rats.
conclusionhUCMSC-exos attenuate ICH-induced glycolysis, lactylation modification, and excessive neuroinflammation via the PI3K/AKT/PKM2/H3K18la axis, offering a novel therapeutic strategy for ICH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.